Complaints to the city from frustrated residents about windrows — piles of snow left at the end of driveways after plows clear the road — have been on the rise this winter. As it stands, homeowners ...
Based on these postmarketing reports, the FDA is evaluating the need for further regulatory action. The Food and Drug Administration (FDA) is investigating the risk of developing neutralizing ...
The FDA said it has received postmarketing reports of neutralizing antibodies to ADAMTS13, including one death, in patients with congenital thrombotic thrombocytopenic purpura (cTTP) who were treated ...
Rained-on hay plagues all of us eventually. The “windrow disease” that often follows presents lingering problems. Windrow disease—that’s the name given to the striped appearance in fields where ...
Takeda’s Adzynma (rADAMTS13) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat congenital thrombotic thrombocytopenic purpura (cTTP). The enzyme replacement ...
MIDLOTHIAN, Texas, Dec. 10, 2024 /PRNewswire/ -- Commercial Truck and Trailer Parts ("CTTP"), a national distributor of aftermarket parts for the U.S. heavy-duty truck industries has partnered with ...
The European Commission (EC) has granted approval to Takeda for ADZYNMA (recombinant ADAMTS13) - the first and only enzyme replacement therapy in the European Union (EU) for congenital thrombotic ...
− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...
OSAKA, Japan & CAMBRIDGE, Mass. - Takeda Pharmaceutical Company (NYSE:TAK) Limited (TSE:4502/NYSE:TAK) has received approval from the European Commission for ADZYNMA® (recombinant ADAMTS13), a new ...
Takeda’s recombinant ADAMTS13 (rADAMTS13) has been recommended by the European Medicines Agency’s human medicines committee to treat ADAMTS13 deficiency in children and adults with congenital ...
OSAKA, Japan & CAMBRIDGE, Mass. - Takeda Pharmaceutical Company (NYSE:TAK) Limited (TSE:4502/NYSE:TAK) has received a positive opinion from the European Medicines Agency's (EMA) Committee for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results